Tollovir™: 3CL Protease Inhibitor
A highly potent 3CL protease inhibitor as a COVID-19 pharmaceutical
Phase 2 Drug Candidate for COVID-19
Todos is developing a more concentrated version of Tollovid for COVID-19 infected patients, using a proprietary blend of botanical extracts with an active chemical ingredient that limits replication of coronaviruses. Todos is currently supporting randomized, placebo-controlled clinical trials managed by JV partner NLC Pharma in Israel. Tollovir is the result of over 15 years of development and an investment of over $18M to date.